(Doc Name H:\LEGWORK\HOUSE\AMEND\H-WM\008\SICKLE CELL DISEASE STUDY COMMITTEE X2.DOCX):
EXPLANATION: Sickle Cell Disease Study Committee
Amend the bill, as and if amended, Part IB, Section 117, GENERAL
PROVISIONS, page 559, after line 20, by adding an appropriately
numbered paragraph to read:
//(GP: Sickle Cell Disease Study Committee): Of the funds
authorized and appropriated to the Department of Health and
Environmental Control, a Sickle Cell Disease Study Committee
shall be created and charged with better serving adults with
sickle cell disease (SCD), health care providers, and the public
about State care and treatment. The committee is to examine
existing services and resources available to children with the
disease as well as adults with the disease. Additionally, the
committee is to establish partnerships with institutions, and
communities, a statewide network of service providers for adults
with the disease; a comprehensive education and treatment
program for adults, as well as establish standardized treatment
and emergency room protocols.
Membership of the committee shall be comprised of
thirteen members as follows:
1) one researcher or physician from the Medical
University of South Carolina specializing in hematology;
2) one researcher or physician from the Children's
Hospital Sickle Cell Clinic at the Medical University of South
Carolina;
3) one citizen with Sickle Cell Disease;
4) one parent or caregiver of an individual with Sickle
Cell Disease;
5) the Executive Director of the SC Hospital Association
or their designee;
6) the President of the South Carolina Medical
Association or their designee;
7) the Superintendent of Education or their designee;
8) the Director of the Department of Health and
Environmental Control or their designee;
9) the Director of the Department of Health and Human
Services or their designee;
10) two members of the House of Representatives appointed
by the Speaker of the House, one of whom the Speaker shall
designate as a co-chair of the study committee; and
11) two members of the Senate appointed by the President
Pro Tempore of the Senate, one of whom the President Pro Tempore
shall designate as a co-chair of the study committee.
The study committee also may invite representatives of
nonprofit entities with expertise regarding Sickle Cell Disease
to participate in the study committee process.
The House of Representatives Medical, Military and
Municipal Affairs Committee and the Senate Medical Affairs
Committee shall designate staff to assist the study committee.
The study committee shall provide a report with findings
and recommendations to the General Assembly and the Governor by
June 30, 2016, at which time the study committee shall dissolve.
/
Renumber sections to conform.
Amend totals and titles to conform.